Utepreva LLC is a New York–based company established in 2020. The company is responsible for the manufacturing and commercialization of the Utepreva device. Utepreva LLC is led by CEO Dr. Jeanetta Stega and Chief Financial & Medical Officer
Dr. Damian Stega, who jointly oversee strategic development, regulatory execution, and operational leadership.
Utepreva LLC works in close partnership with the Utepreva Distribution Company, which manages all national sales activities for the device. The distribution arm is guided by experienced commercial leaders, Tom Muscarella and Peter Faulisi, ensuring strong market reach and effective deployment across clinical and healthcare networks.
Uterine Cancer is the most common type of gynecologic cancer. It's estimated that about 65,950 new diagnosed in 2022, and by 2030 this number will rise to 122,000.
Uterine cancer is rapidly becoming a public health crisis.
Diagnosis today typically occurs only after symptom onset (e.g., post-menopausal bleeding), most cases are already at risk of being advanced. Survival rates reach up to 95% when caught early but fall below 20% for advanced stages.
There is currently no standardized approach for routine early detection. This creates a substantial unmet need and exposes patients to preventable morbidity, mortality, and cost escalation.

Utepreva is directly aligned with the strategic priorities being amplified by global industry leaders: improving early detection, expanding equitable access, and addressing one of the most overlooked gaps in women’s cancer care. As a patented, single-use device designed specifically for rapid, in-office uterine sampling, Utepreva enables clinicians to perform the procedure quickly, safely, and cost-effectively—without the need for specialized equipment or operating room. This allows the device to fit seamlessly into routine clinical workflow and makes widescale adoption feasible across a broad range of healthcare settings, from large health systems to community practices.
Utepreva’s tissue collection is achieved through a unique combination of suction, disruption, and absorption, enabling high-quality retrieval of both cellular and fluid-based samples.
100 Jericho Quadrangle, Jericho, NY, USA